3.48
-0.05 (-1.42%)
| Previous Close | 3.53 |
| Open | 3.47 |
| Volume | 201,393 |
| Avg. Volume (3M) | 123,922 |
| Market Cap | 145,565,696 |
| Price / Sales | 2.85 |
| Price / Book | 10.53 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2026 |
| Profit Margin | -42.37% |
| Operating Margin (TTM) | -32.35% |
| Diluted EPS (TTM) | -0.540 |
| Quarterly Revenue Growth (YOY) | -7.90% |
| Total Debt/Equity (MRQ) | 365.61% |
| Current Ratio (MRQ) | 5.45 |
| Operating Cash Flow (TTM) | -12.41 M |
| Levered Free Cash Flow (TTM) | -7.30 M |
| Return on Assets (TTM) | -14.60% |
| Return on Equity (TTM) | -129.51% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Bearish |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | Apyx Medical Corporation | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | 4.0 |
| Average | 0.63 |
|
Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Advanced Energy and Original Equipment Manufacturing (OEM). Its Advanced Energy segment derives the majority of its revenue. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Value |
| % Held by Insiders | 14.56% |
| % Held by Institutions | 43.51% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 6.00 (Craig-Hallum, 72.41%) | Buy |
| 6.00 (BTIG, 72.41%) | Buy | |
| Median | 6.00 (72.41%) | |
| Average | 6.00 (72.41%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 3.93 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BTIG | 11 Mar 2026 | 6.00 (72.41%) | Buy | 3.93 |
| Craig-Hallum | 11 Mar 2026 | 6.00 (72.41%) | Buy | 3.93 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 29 Jan 2026 | Announcement | Apyx Medical Corporation to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference |
| 12 Jan 2026 | Announcement | Apyx Medical Corporation Reports Preliminary, Unaudited, Fourth Quarter and Full Year 2025 Revenue Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |